FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912815071> ?p ?o ?g. }

• W2912815071 abstract "Soft tissue sarcoma (STS) are rare mesenchymal-originated tumors with more than 50 different histologies identified. Not every histology in STS responds to immunotherapy and immunologic predictive markers are lacking. The purpose of this study is to establish an immune classification of STS by analysis of the transcriptome. This was performed by using a deconvolution method that allowed us to quantify 8 immune populations and endothelial cells. As a secondary objective, we searched for a surrogate biomarker that could be assessable in the clinic. We analyzed transcriptomic data of four publicly available datasets, accounting for 608 complex genomic STS, including leiomyosarcoma (LMS, 35.4%), dedifferentiated liposarcoma (DDLPS, 33.9%) and undifferentiated pleomorphic sarcoma (UPS, 30.8%). By using the MCP-Counter deconvolution method, we characterized the tumor microenvironment (TME) of these tumors and established a robust immune classification that is consistent through various cohorts. We classified the patients into 5 Sarcoma Immune Classes (SIC), labeled as A1, A2, B, C1 and C2. The A1 and A2 groups are associated with very low to low immune infiltrates. Conversely, SIC C1 and C2 tumors are characterized by strong to very strong expression of signatures associated to all immune cells. SIC B tumors are characterized by a high expression of endothelial cell signature, an intermediate presence of neutrophils, and a rather low infiltration by other immune cell types. Regarding functional orientation of the TME, gene signatures associated with immune cells chemotaxis activation and survival, expression of major histocompatibility complex class I, and regulatory T-cells are highly expressed in SIC C1 and C2, modestly expressed in B and A2, and very lowly expressed in A1. Interestingly, immune checkpoint genes exhibited strong expression differences between SICs. SIC C2 had a strong expression of PD-1, PD-L2, CTLA-4 and TIM-3 genes. We also found that the lymphoid structure-associated B cell chemoattractant chemokine CXCL13 is remarkably highly expressed in C2 class. CXCL13 is associated with the presence of tertiary lymphoid structures (TLS). Although all histologies are distributed in each SIC group, LMS are more commonly found in the immune low SIC A1 and A2 groups, and we also extended our analysis to other histologies such as synovial sarcoma or gastrointestinal stromal tumors. Our classification is associated with clinical outcome, and SIC group C (C1/C2) has the longest overall survival, as compared to SIC A group (A1/A2) (p = 0.015). We then validated SIC classification using STS FFPE samples (n=32). SIC classification by RNA expression was correlated with quantitative immunohistochemistry (IHC) of CD3 (T-cells), DC-Lamp (activated dendritic cells), CD20 (B cells), CD8 (CD8+ T-cells), and CD34 (endothelial cells). Densities of CD3 (p=0.0033), CD8 (p=0.004) and CD20 (p=0.00043) were significantly higher in SIC C tumors. Tumor SIC B groups have a higher, albeit nonsignificant (p=0.6) expression of CD34+ endothelial cells. In the validation cohort, SIC group C is associated with a better prognosis (p=0.053). We further investigated whether TLS were a marker of the immune-high SIC C group. Not surprisingly, TLS-positive tumors were found only in SIC C2 (100%, 9/9) and C1 (50%, 3/6) groups of the validation cohort. We expanded the validation cohort (n = 93) to analyze the correlation between TLS and CD3+/CD8+/CD20+ tumor-infiltrating lymphocytes. We found that the presences of each type of TILs all are significantly associated with the presence of TLS (CD3, CD8, CD20, all p values Citation Format: Wei-Wu Tom Chen, Florent Petitprez, Cheng-Ming Sun, Laetitia Lacroix, Aurelien de Reynies, Antoine Italiano, Maud Toulmonde, Carlo Lucchesi, Yec9han Laizet, Catherine Sautes-Fridman, Wolf Herve Fridman. Immune-based classification of soft-tissue sarcoma is associated with clinical outcome and unveils tertiary lymphoid structures as surrogate biomarker for the clinic [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr PR03." @default.
• W2912815071 created "2019-02-21" @default.
• W2912815071 creator A5010029786 @default.
• W2912815071 creator A5015718270 @default.
• W2912815071 creator A5031619074 @default.
• W2912815071 creator A5037236636 @default.
• W2912815071 creator A5042627121 @default.
• W2912815071 creator A5054880022 @default.
• W2912815071 creator A5060949051 @default.
• W2912815071 creator A5066182456 @default.
• W2912815071 creator A5084836759 @default.
• W2912815071 creator A5088506812 @default.
• W2912815071 creator A5091574686 @default.
• W2912815071 date "2019-02-01" @default.
• W2912815071 modified "2023-10-16" @default.
• W2912815071 title "Abstract PR03: Immune-based classification of soft-tissue sarcoma is associated with clinical outcome and unveils tertiary lymphoid structures as surrogate biomarker for the clinic" @default.
• W2912815071 doi "https://doi.org/10.1158/2326-6074.cricimteatiaacr18-pr03" @default.
• W2912815071 hasPublicationYear "2019" @default.
• W2912815071 type Work @default.
• W2912815071 sameAs 2912815071 @default.
• W2912815071 citedByCount "0" @default.
• W2912815071 crossrefType "proceedings-article" @default.
• W2912815071 hasAuthorship W2912815071A5010029786 @default.
• W2912815071 hasAuthorship W2912815071A5015718270 @default.
• W2912815071 hasAuthorship W2912815071A5031619074 @default.
• W2912815071 hasAuthorship W2912815071A5037236636 @default.
• W2912815071 hasAuthorship W2912815071A5042627121 @default.
• W2912815071 hasAuthorship W2912815071A5054880022 @default.
• W2912815071 hasAuthorship W2912815071A5060949051 @default.
• W2912815071 hasAuthorship W2912815071A5066182456 @default.
• W2912815071 hasAuthorship W2912815071A5084836759 @default.
• W2912815071 hasAuthorship W2912815071A5088506812 @default.
• W2912815071 hasAuthorship W2912815071A5091574686 @default.
• W2912815071 hasConcept C104317684 @default.
• W2912815071 hasConcept C142724271 @default.
• W2912815071 hasConcept C150194340 @default.
• W2912815071 hasConcept C162317418 @default.
• W2912815071 hasConcept C203014093 @default.
• W2912815071 hasConcept C2776107976 @default.
• W2912815071 hasConcept C2777701055 @default.
• W2912815071 hasConcept C2778256501 @default.
• W2912815071 hasConcept C2778629024 @default.
• W2912815071 hasConcept C502942594 @default.
• W2912815071 hasConcept C55493867 @default.
• W2912815071 hasConcept C71924100 @default.
• W2912815071 hasConcept C86803240 @default.
• W2912815071 hasConcept C8891405 @default.
• W2912815071 hasConceptScore W2912815071C104317684 @default.
• W2912815071 hasConceptScore W2912815071C142724271 @default.
• W2912815071 hasConceptScore W2912815071C150194340 @default.
• W2912815071 hasConceptScore W2912815071C162317418 @default.
• W2912815071 hasConceptScore W2912815071C203014093 @default.
• W2912815071 hasConceptScore W2912815071C2776107976 @default.
• W2912815071 hasConceptScore W2912815071C2777701055 @default.
• W2912815071 hasConceptScore W2912815071C2778256501 @default.
• W2912815071 hasConceptScore W2912815071C2778629024 @default.
• W2912815071 hasConceptScore W2912815071C502942594 @default.
• W2912815071 hasConceptScore W2912815071C55493867 @default.
• W2912815071 hasConceptScore W2912815071C71924100 @default.
• W2912815071 hasConceptScore W2912815071C86803240 @default.
• W2912815071 hasConceptScore W2912815071C8891405 @default.
• W2912815071 hasLocation W29128150711 @default.
• W2912815071 hasOpenAccess W2912815071 @default.
• W2912815071 hasPrimaryLocation W29128150711 @default.
• W2912815071 hasRelatedWork W14743255 @default.
• W2912815071 hasRelatedWork W2151330 @default.
• W2912815071 hasRelatedWork W2495403 @default.
• W2912815071 hasRelatedWork W2773312 @default.
• W2912815071 hasRelatedWork W4041773 @default.
• W2912815071 hasRelatedWork W4853054 @default.
• W2912815071 hasRelatedWork W5786864 @default.
• W2912815071 hasRelatedWork W6417289 @default.
• W2912815071 hasRelatedWork W746658 @default.
• W2912815071 hasRelatedWork W9749177 @default.
• W2912815071 isParatext "false" @default.
• W2912815071 isRetracted "false" @default.
• W2912815071 magId "2912815071" @default.
• W2912815071 workType "article" @default.